List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 1172 studies with search of: melanoma
Hide studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Recruiting Characterization of the Melanoma-Specific Immune Response
Condition: Melanoma
Intervention:
2 Unknown † Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
Conditions: Advanced Melanoma;   Untreated Patients
Interventions: Drug: dacarbazine plus Endostar (Experimental group);   Drug: dacarbazine plus placebo (control group)
3 Completed
Has Results 		MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
4 Recruiting Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
Condition: Melanoma
Interventions: Biological: melanoma GVAX;   Drug: Cyclophosphamide
5 Completed Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma
Condition: Melanoma
Interventions: Drug: low-dose IL-2;   Biological: melanoma vaccine
6 Completed Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: melanoma helper peptide vaccine;   Biological: multi-epitope melanoma peptide vaccine;   Biological: sargramostim;   Biological: tetanus peptide melanoma vaccine
7 Active, not recruiting Melanoma Risk-Reduction Among Patients and Family Members
Condition: Melanoma
Interventions: Behavioral: Questionnaire;   Behavioral: Interview
8 Active, not recruiting Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma
Condition: Melanoma
Intervention: Biological: Class 4 and Class 12 melanoma peptide vaccines
9 Not yet recruiting Melanoma Margins Excision Trial
Condition: Melanoma
Intervention: Procedure: Surgical Excision Margin
10 Recruiting Vaccination Plus Ontak in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: 4-peptide melanoma vaccine;   Drug: 4-peptide melanoma vaccine plus Ontak;   Drug: ontak
11 Unknown † Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: melanoma helper peptide vaccine;   Biological: multi-epitope melanoma peptide vaccine;   Biological: tetanus toxoid helper peptide;   Drug: cyclophosphamide
12 Recruiting Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
Conditions: Hereditary Multiple Melanoma;   Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: molecular genetic technique;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Procedure: mutation carrier screening;   Procedure: study of high risk factors
13 Completed Comparison of Video-Based Versus Written Patient Education on Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Other: Patient Educational Materials
14 Recruiting Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes
Condition: Melanoma (Skin)
Interventions: Biological: HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine;   Biological: HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine;   Biological: autologous melanoma lysate-pulsed autologous dendritic cell vaccine;   Biological: autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine;   Biological: dendritic cell-idiotype-keyhole limpet hemocyanin vaccine;   Other: flow cytometry;   Procedure: adjuvant therapy
15 Unknown † Vaccine Therapy in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: QS21;   Biological: incomplete Freund's adjuvant;   Biological: peptide 946 melanoma vaccine;   Biological: peptide 946-tetanus peptide conjugate melanoma vaccine;   Biological: tetanus peptide melanoma vaccine
16 Recruiting Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
17 Recruiting Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients
Condition: Melanoma
Intervention: Other: biological collection
18 Completed Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
Conditions: Stage IV Melanoma;   Recurrent Melanoma
Intervention: Biological: recombinant interferon beta
19 Active, not recruiting M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Condition: Melanoma
Intervention: Biological: M-Vax- autologous, hapten-modified melanoma vaccine
20 Unknown † A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma
Condition: Melanoma
Interventions: Biological: HyperAcute vaccine;   Drug: Pegylated Interferon-Alpha 2b

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services